Trials / Unknown
UnknownNCT00745511
Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Ora Bio Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular age related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ORA102 and Avastin | treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102 |
| DRUG | Avastin | treatment with intravitreal injections of Avastin 1.25mg (0.05ml) |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2008-09-03
- Last updated
- 2009-06-09
Locations
5 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT00745511. Inclusion in this directory is not an endorsement.